Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
FDA Status: Not yet approved (currently in Phase 3 clinical trials) How It Works: Stimulates GLP-1, GIP, and glucagon receptors to enhance metabolism, burn fat, and suppress appetite Common Side Effects (in trials): Nausea, mild vomiting, transient fatigue, and slight increases in heart rate Expected Weight Loss Results: Early studies suggest greater average weight loss than both semaglutide and tirzepatide Because its still under investigation, retatrutides availability is limited to clinical trial participants or research programs until FDA approval is secured
It is important to note that real-world results from these therapies often differ from the results from controlled clinical trials
20321 Irvine Avenue, Suite #F3, Newport Beach, CA 92660 Mon-Fri: 9am 5pm 36943 Cook St
In such patients, glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide, may be helpful in lowering body weight while also reducing blood glucose
US$ 25.79
US$ 23.15
US$ 24.20
US$ 27.87
